No abstract available.
Histiocytosis*

No abstract available.
Neurofibromatoses* ; Peripheral Nerves*

No abstract available.
Cyclosporine* ; Humans ; Vitiligo*

No abstract available.
Animals ; Horns* ; Keratoacanthoma*

Kerion celsi is an inflammatory dermatophytosis of the scalp which is characterized by an acute suppurative process caused mainly by zoophilic dermatophytes. Systemic corticosteroid can be added to systemic antifungal treatment for reducing scarring alopecia, but focal cicatricial changes are unavoidable in a severe case. We report a case of kerion celsi caused by T. mentagrophytes, zoophilic dermatophyte, in a 7-year-old girl. This patient had localized painful erythematous crusted plaques with multiple inflammatory pustules on the scalp. Although she was initially treated with antifungal agent and systemic corticosteroid, focal scarring alopecia occurred eventually. Eventually, the cicatricial change was corrected surgically after two and a half years in spite of timely and appropriate treatment.
Alopecia ; Arthrodermataceae ; Child ; Cicatrix ; Humans ; Scalp ; Tinea ; Tinea Capitis

No abstract available.
Acneiform Eruptions*

BACKGROUND: Atrophic acne scars have been treated using various modalities. The CROSS (Chemical Reconstruction of Skin Scars) technique using 100% TCA has the advantage of reconstructing acne scars by focusing on dermal thickening and collagen production. However, the phenol CROSS technique is not widely used for acne scarring. OBJECTIVE: The purpose of this study was to evaluate the clinical effectiveness and safety of 100% TCA CROSS and phenol CROSS in the treatment of facial atrophic acne scars. METHODS: Twenty-four participants were randomly and equally divided into 2 groups: group 1 received 2 sessions (8 weeks apart) of 100% TCA CROSS, while group 2 received 2 sessions (8 weeks apart) of phenol CROSS. The severity of atrophic acne scarring and treatment efficacies were evaluated by standardized photography, patient satisfaction, physician global assessment, and the ECCA grading scale. Side effects were assessed at the 8- and 20-week visits. RESULTS: At the 0-, 8-, and 20-week visits, both groups showed an acceptable improvement in patient satisfaction and physician global assessment. ECCA grading scale scores improved by a mean of 22.2% (p<0.05) in group 1 and 19.1% (p<0.05) in group 2. The between-group difference in the degree of ECCA score improvement was not statistically significant (p=0.392). Complications such as pain, crust, postcrust erythema, postcrust dryness, and postinflammatory hyperpigmentation were observed in both treatment groups. However, no severe side effects occurred in either group. CONCLUSION: Both 100% TCA CROSS and phenol CROSS are effective treatment modalities for atrophic acne scarring without significant side effects.
Acne Vulgaris* ; Cicatrix* ; Collagen ; Erythema ; Hyperpigmentation ; Patient Satisfaction ; Phenol* ; Photography ; Skin ; Trichloroacetic Acid

No abstract available.
Leiomyosarcoma* ; Neoplasm Metastasis* ; Scalp* ; Skin

No abstract available.
Exanthema* ; Humans ; Infant* ; Leukemia* ; Leukemia, Myeloid, Acute

BACKGROUND: The aim of this in vitro study was to determine the effect of zoledronate, which is frequently used to treat osteoporosis, on osteoarthritis by analyzing zoledronate-induced expression of vascular endothelial growth factor-A (VEGF-A) in chondrocytes and synovial cells. METHODS: After chondrocytes and synovial cells were separated and cultured, zoledronate was added, and VEGF-A and pigment epithelium-derived factor (PEDF) expression were quantified by real-time polymerase chain reaction and Western blotting. RESULTS: There was no significant difference in the expression of VEGF-A mRNA in chondrocytes between the zoledronate group and the control group on the 8th day of culture. The expression of both VEGF-A and PEDF mRNA in synovial cells was significantly decreased in the zoledronate group (P<0.05). CONCLUSIONS: Zoledronate decreases the expression of VEGF-A in synovial cells and may affect the development and progression of osteoarthritis.
Blotting, Western ; Chondrocytes* ; Osteoarthritis ; Osteoporosis ; Real-Time Polymerase Chain Reaction ; RNA, Messenger ; Vascular Endothelial Growth Factor A*